Pharming Group N.V. ADS, each representing 10 ordinary
N/A
USD
N/A
N/A
...
Chart
Financials
Description
PHAR Company Description
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
PHAR Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view PHAR Smart Score
Score Breakdown
PHAR Company Description
Show More
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of PHAR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PHAR's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on PHAR's company Twitter account
WallStreetBets
Number of mentions of PHAR in WallStreetBets Daily Discussion
PHAR News
Recent insights relating to PHAR
CNBC Recommendations
Recent picks made for PHAR stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in PHAR
Corporate Flights
Flights by private jets registered to PHAR
Our Analysis